Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹7,074 Cr
verified against source
Revenue YoY
0%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY). PAT of INR 676 crore included a one-time INR 276 crore labor code charge. U.S. revenue fell to $167 million as Lenalidomide tapered and lanreotide supply was disrupted (partner Pharmathen paused production after FDA observations; resupply expected H1 FY27). India business grew 10% YoY, with respiratory crossing INR 5,000 crore. FY26 EBITDA margin guidance revised to ~21%. Key upcoming U.S. launches (4 respiratory, 4 peptide assets) are expected to offset revenue declines, but near-term headwinds persist. Risk: lanreotide disruption may extend beyond H1 FY27 if remediation is delayed.
Colored figures show movement against the previous available record.
Guidance to track
- Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact.
- Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza.
- Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway.
- Management will provide FY27 guidance after finalizing the annual operating plan.
Risks flagged
- Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.
- Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.
- R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.
- Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive.
Key quotes
- We expect upcoming launches to help cushion the decline in Lenalidomide revenues and provide long-term growth.
- The guidance will have to be revised because if we don't have lanreotide in one quarter, the numbers will be lower.
- If you take out Lenalidomide, and if you take the next top 2 or 3 products of the company that we sell, including lanreotide, this is ballpark in that top 2 or top 3 product type of a profile.
Research modules